Why CanniMed Therapeutics Inc. Soared 17.18% on Thursday

CanniMed Therapeutics Inc. (TSX:CMED) soared 17.18% on Thursday after announcing that it will discuss a possible deal with Aurora Cannabis Inc. (TSX:ACB). What should you do now?

| More on:
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

What?

Canadian medical cannabis producer CanniMed Therapeutics Inc. (TSX:CMED) watched its stock roar 17.18% higher in Thursday’s trading session following its announcement that it has postponed its special shareholders’ meeting to vote on its proposed takeover of Newstrike Resources Ltd. (TSXV:HIP) in order to discuss a possible transaction with Aurora Cannabis Inc. (TSX:ACB).

So what?

Aurora had originally tried to acquire CanniMed in November, but CanniMed was not a fan of the deal and has done everything in its power to prevent it, including launching its takeover of Newstrike Resources and filing a $725 million lawsuit against Aurora, but it seems like the two sides are finally on speaking terms and will meet to discuss a potential deal.

Aurora has been accumulating shares of CanniMed since announcing its intention to take the company over on November 24, with its most recent press release showing an aggregate number of shares purchased at 700,600, which have a market value of approximately $22.84 million at the close of trading on Thursday, but it has agreed to not acquire any additional shares during the standstill period that will last until January 21 at 11:59 P.M. (EST).

Now what?

Cannabis is right up there with cryptocurrency and blockchain technology as one of the most-talked-about topics in the investment world today, especially in Canada, and it has been one of the most active in terms of deal making as well. I think a deal between CanniMed and Aurora would make the combined company an absolute powerhouse in the industry with far greater long-term growth potential, and it would give it elite status alongside Canopy Growth Corp. and Aphria Inc. in my mind, so I am definitely rooting for the deal to get done. 

With all of this being said, I would avoid making new investments in CanniMed or Aurora until we know more about the possible deal on January 21, so stay tuned!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joseph Solitro has no position in any stocks mentioned.

More on Investing

Investing

KM Throwaway Post

Read more »

Investing

Carlos Test Yoast Metadata

Read more »

Investing

KM Ad Test

This is my excerpt.

Read more »

Investing

Test post for affiliate partner mockups

Updated: 9/17/2024. This post was not sponsored. The views and opinions expressed in this review are purely those of the…

Read more »

Investing

Testing Ecap Error

Premium content from Motley Fool Stock Advisor We here at Motley Fool Stock Advisor believe investors should own at least…

Read more »

Investing

TSX Today: Testing the Ad for James

la la la dee dah.

Read more »

Lady holding remote control pointed towards a TV
Investing

2 Streaming Stocks to Buy Now and 1 to Run From

There are streaming stocks on the TSX that are worth paying attention to in 2023 and beyond.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Stocks for Beginners

Top Recession-Resilient TSX Stocks to Buy With $3,000

It's time to increase your exposure to defensives!

Read more »